Testing a neuroprotective drug for recent stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial studies the safety and effectiveness of edaravone, a neuroprotective drug, in people who have had a mild to moderate stroke in the front part of the brain within the last 48 hours. It aims to see if this drug can help protect the brain from further damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have had a mild or moderate ischemic stroke (a clot in the front part of the brain) within the past 48 hours.
- You must be taking or planning to take the drug edaravone.
- You must be mostly independent before the stroke, able to live without needing daily help from others.
- You must not have had any bleeding in the brain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called edaravone dexborneol for people who have had an acute ischemic stroke (a stroke caused by a blood clot). The goal is to see if it is safe and helps improve recovery when given within 48 hours of the stroke starting.
This trial tests if a sublingual (under the tongue) medication called Edaravone Dexborneol can help stroke patients who are being transferred from one hospital to another for a specialized procedure to remove a clot.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
This trial tests a drug called Human Urinary Kallidinogenase to see if it can help people recover better after a recent stroke caused by a blockage in the front part of the brain. It is for patients who have mild to moderate symptoms and can start treatment within 2 days of the stroke.
This trial tests a clot-dissolving medication (pro-urokinase) for people with recent strokes in the back of the brain. You would be treated 4.5 to 9 hours after symptoms start, which is beyond the typical treatment window, using special MRI patterns to identify patients most likely to benefit.
This trial tests a new drug, HRS-4029, given within 3 hours of an ischemic stroke (a stroke caused by a blocked blood vessel). The goal is to see if the drug helps improve recovery.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.